Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04554394
Other study ID # NP-WP-010
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 17, 2019
Est. completion date December 1, 2020

Study information

Verified date June 2023
Source Pulse Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.


Description:

The study will enroll healthy adult subjects with a minimum of two cutaneous non-genital warts, excluding the face, with each wart lesion not exceeding 10 x 10mm. One of the warts for each subject will be untreated and will serve as the subject's internal control. Macrophotography of all study warts will be captured along with Investigator assessments using the Wart Measurement Scale (WMS) and lesion measurements for wart reduction. All subjects will be followed at 7, 30, 60, 90 and 120-days post-initial CellFX treatment. All wart lesions are eligible for re-treatment up to 3 times over the course of the study. Adverse events will be documented.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date December 1, 2020
Est. primary completion date June 9, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Subjects must be at least 21 and not older than 80 years of age - Subjects must be able to read and speak English or Spanish - Subjects must sign a written informed consent to participate in the study, prior to any study related procedures - Subject must have a minimum of two cutaneous non-genital warts, each not exceeding 10 x 10mm - Subject is willing to undergo all study-mandated procedures - Subject agrees to refrain from using all other wart removal products or treatments (topical medication including over-the-counter medications) during the study period Exclusion Criteria: - Subject has an implantable electronic medical device. (pacemaker, implantable cardioverter defibrillator, etc.) - Subject has cochlear implants - Subject has an active systemic infection or history of an infection in the designated treatment area within 90 days of enrollment - Subject has a history of and/or current tinnitus - Subject is known to be immune-compromised - Subject is taking a blood thinning medication (Antiplatelet, Anticoagulation, Factor Xa Inhibitor, etc.) - Subject has Type 1 Diabetes and is insulin dependent - Subject has a known allergy to Lidocaine or Lidocaine-like products - Subject is a member of a vulnerable population including individuals employed by the Sponsor, clinic site, or entity associated with the conduct of the study - Subject has a comorbidity or condition which may reduce compliance with this protocol, including follow-up visits - Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CellFX Device
The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.

Locations

Country Name City State
United States Dermatology, Laser & Vein Specialists of the Carolinas, PLLC Charlotte North Carolina
United States Austin Institute for Clinical Research, Inc. Pflugerville Texas
United States Skin Search of Rochester, Inc. Rochester New York
United States Scripps Clinic Carmel Valley San Diego California
United States Investigate MD, LLC Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Pulse Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Verrucae Cleared Percentage of Verrucae with Clearance (91-100% reduction) 60-days post-last CellFX treatment
Secondary Subject Satisfaction Satisfaction with reduction in verrucae size or clearance of verrucae measured using the following scale; 5 (Satisfied), 4 (Mostly Satisfied), 3 (Partially Satisfied), 2 (Dissatisfied), 1 (Highly Dissatisfied) 60-days post-last CellFX treatment
See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT00546611 - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) Phase 1
Completed NCT00117871 - Study With a Topical Gel to Treat Common Warts in Adults Phase 2
Completed NCT04278573 - Intralesional Vitamin D Injection for Treatment of Common Warts Phase 2
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Completed NCT06309420 - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts N/A
Not yet recruiting NCT05616078 - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts N/A
Not yet recruiting NCT05617950 - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts N/A
Recruiting NCT01712295 - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Phase 4
Active, not recruiting NCT00254280 - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial N/A
Completed NCT04781244 - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment N/A
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Recruiting NCT05625633 - Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Phase 2/Phase 3
Completed NCT02393417 - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Phase 2
Completed NCT01808443 - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts N/A
Completed NCT00116675 - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00116662 - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2